Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Name||non-invasive bladder urothelial carcinoma|
|Path||disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder urothelial carcinoma non-invasive bladder urothelial carcinoma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00794950||Phase II||Sunitinib||Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma||Completed|
|NCT03317158||Phase Ib/II||Durvalumab BCG solution + Durvalumab||ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder||Recruiting|
|NCT03672240||Phase Ib/II||APL-1202 APL-1202 + BCG solution||Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC)||Completed|
|NCT04149574||Phase III||BCG solution + Nivolumab BCG solution||A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)||Recruiting|
|NCT04172675||Phase II||Erdafitinib Gemcitabine Mitomycin C||A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)||Recruiting|